Skip to content

SEC filer · CIK 0000949858 · ACHV

Achieve Life Sciences, Inc.

Achieve Life Sciences net income: -$54.6 million for the year ending 2025-12-31. Total assets: $41.8 million at 2025-12-31.

Latest annual reportReceipt

10-K for the fiscal year ended , filed

Net income
-$54.6 million
Diluted EPS
-$1.25 per share
Operating cash flow
-$49.5 million
Cash
$20.9 million
Total assets
$41.8 million
Total liabilities
$20.3 million

As filed

Open the 10-K on SEC.gov
The figures the company tagged in that report. Each opens its full history below.

Context from the filing

For 2023–2025, Achieve reports equal basic and diluted net loss per share and describes excluding potentially issuable shares because they are anti-dilutive. Shares and per-share amounts are exempt from the thousands heading. The note’s excluded-instrument total uses inconsistent million-shares wording alongside individual counts; that narrative total is not the weighted-average denominator and is not substituted here. The selected EPS and weighted-average figures remain as reported. Read the source filing.

Every reported measure

The latest value of each measure the company reports, as filed. Choose one for its full history, its definition and the filing behind each figure. Separate currencies and reporting intervals stay separate rows; these are reported amounts, not prices.

Latest value of each measure
MeasurePeriod startPeriod endValueFiled
Total assets-2025-12-31$41.8 million2026-03-24
Total liabilities-2025-12-31$20.3 million2026-03-24
Stockholders equity-2025-12-31$21.5 million2026-03-24
Cash and cash equivalents-2025-12-31$20.9 million2026-03-24
Net income or loss2025-01-012025-12-31-$54.6 million2026-03-24
Operating cash flow2025-01-012025-12-31-$49.5 million2026-03-24
Capital expenditure payments2025-01-012025-12-31$30002026-03-24
Financing cash flow2025-01-012025-12-31$51.5 million2026-03-24
Investing cash flow2025-01-012025-12-31$6.11 million2026-03-24
Retained earnings or deficit-2025-12-31-$260.2 million2026-03-24
Basic weighted-average shares2025-01-012025-12-3143.6 million shares2026-03-24
Diluted weighted-average shares2025-01-012025-12-3143.6 million shares2026-03-24
Basic earnings per share2025-01-012025-12-31-$1.25 per share2026-03-24
Diluted earnings per share2025-01-012025-12-31-$1.25 per share2026-03-24
Net property, plant and equipment-2025-12-31$30002026-03-24
Share-based compensation expense2025-01-012025-12-31$8.76 million2026-03-24
Current assets-2025-12-31$39.9 million2026-03-24
Current liabilities-2025-12-31$9.08 million2026-03-24
Current accounts payable-2024-12-31$1.95 million2025-03-11
Net finite-lived intangible assets-2025-12-31$751.0 thousand2026-03-24
Research and development expense2024-01-012024-12-31$22.8 million2025-03-11
Common shares outstanding-2025-12-3153.2 million shares2026-03-24
Accumulated other comprehensive income or loss-2025-12-31$10.0 thousand2026-03-24
Operating lease right-of-use asset-2025-12-31$64.0 thousand2026-03-24
Gross property, plant and equipment-2025-12-31$256.0 thousand2026-03-24
Accumulated depreciation on property, plant and equipment-2025-12-31$253.0 thousand2026-03-24
Prepaid expenses and other current assets-2024-12-31$2.11 million2025-03-11
Net deferred tax assets-2025-12-31$283.0 thousand2026-03-24
Pre-tax income or loss from continuing operations2025-01-012025-12-31-$54.6 million2026-03-24
Profit or loss including noncontrolling interests2025-01-012025-12-31-$54.6 million2026-03-24
Comprehensive income or loss2025-01-012025-12-31-$54.7 million2026-03-24
General and administrative expense2024-01-012024-12-31$16.3 million2025-03-11
Nonoperating interest expense2025-01-012025-12-31$819.0 thousand2026-03-24
Other nonoperating income or expense2025-01-012025-12-31-$36.0 thousand2026-03-24
Nonoperating income or expense2025-01-012025-12-31$232.0 thousand2026-03-24
Operating lease payments2025-01-012025-12-31$114.0 thousand2026-03-24
Older measures: 10 not reported in the two years before 2026-09-20
Measures last reported more than two years before capture
MeasurePeriod startPeriod endValueFiled
Income tax expense or benefit2016-01-012016-12-31$02017-02-23
Net current accounts receivable-2019-12-31$80002020-03-13
Operating expenses2015-01-012015-12-31$36.9 million2016-03-09
Cash including restricted cash-2017-12-31$5.56 million2018-03-01
Other noncurrent assets-2020-12-31$187.0 thousand2021-03-11
Net income available to common stockholders2011-01-012011-12-31-$14.7 million2012-03-08
Depreciation expense2021-01-012021-12-31$27.0 thousand2022-03-10
Deferred income tax expense or benefit2017-01-012017-12-31-$3.05 million2018-03-01
Proceeds from issuing common stock2017-01-012017-12-31$64.0 thousand2020-03-13
Change in accounts receivable2019-01-012019-12-31$10002020-03-13

Filings

61 Achieve Life Sciences filings with published measures: what each annual or quarterly report tagged, with the periods it covered, as reported in that filing. The histories above show the latest-filed value per period.

Inspect the source

Entity
Achieve Life Sciences, Inc. / CIK 0000949858
Captured
SEC response SHA-256
99bc74bd7159630b925b01f21dc60b0899467b369bb5a1524cbbfa411e86b911

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

The MCP server is free and MIT-licensed: npx -y canli-mcp. If these records help your research, a star on GitHub helps other researchers find them.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000949858.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))